A Population Pharmacokinetic–Pharmacodynamic Analysis of Repeated Measures Time-to-Event Pharmacodynamic Responses: The Antiemetic Effect of Ondansetron

This paper presents and illustrates methodology for specifying, estimating, and evaluating a predictive model for repeated measures time-to-event responses. The illustrative example specifies a model of the antiemetic effect vs. concentration relationship for the 5-HT3antagonist ondansetron in the human ipecac model for emesis. A key part of this model is a time-dependent log hazard function for emesis that is increased by ipecac administration and decreased by ondansetron concentration. The model is fit using an approximate maximum likelihood method. The data consist of the time free of emeses and, for those individuals with emetic episodes, the time(s) of the episode(s). Model evaluation is accomplished using residual plots adapted to time-to-event data and a “posterior predictive check” wherein observed data statistics are compared to those obtained from data simulated from the fitted model. The ondansetron concentration required to obtain a 50% reduction in the hazard of emesis is estimated to be 1.4±0.2 ng/ml, and the rate constant for elimination of ipecac-induced hazard is 1.5±0.2hr−1.

[1]  C. Felgate,et al.  Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. , 1991, Journal of pharmaceutical sciences.

[2]  David B. Dunson,et al.  Bayesian Data Analysis , 2010 .

[3]  N H Holford,et al.  Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.

[4]  Adrian Dunne,et al.  Analysis of Nonrandomly Censored Ordered Categorical Longitudinal Data from Analgesic Trials , 1997 .

[5]  M. Danhof,et al.  Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. , 1988, Pharmacology & therapeutics.

[6]  D. Harrington,et al.  Counting Processes and Survival Analysis , 1991 .

[7]  L B Sheiner,et al.  A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data , 1994, Clinical pharmacology and therapeutics.

[8]  John D. Kalbfleisch,et al.  The Statistical Analysis of Failure Data , 1986, IEEE Transactions on Reliability.

[9]  Lewis B. Sheiner,et al.  Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[10]  C. Lawlor,et al.  Ipecacuanha‐induced emesis: A human model for testing antiemetic drug activity , 1993, Clinical pharmacology and therapeutics.

[11]  D. Collet Modelling Survival Data in Medical Research , 2004 .

[12]  D. Stanski,et al.  A three-step approach combining bayesian regression and NONMEM population analysis: Application to midazolam , 1991, Journal of Pharmacokinetics and Biopharmaceutics.

[13]  S. Wring,et al.  A sensitive radioimmunoassay, combined with solid-phase extraction, for the sub-nanogram per ml determination of ondansetron in human plasma. , 1994, Journal of pharmaceutical and biomedical analysis.

[14]  W. Colburn,et al.  Efficacy Measures: Surrogates or Clinical Outcomes? , 1996, Journal of clinical pharmacology.

[15]  Xiao-Li Meng,et al.  POSTERIOR PREDICTIVE ASSESSMENT OF MODEL FITNESS VIA REALIZED DISCREPANCIES , 1996 .

[16]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[17]  D R Stanski,et al.  Plasma Concentrations of Alfentanil Required to Supplement Nitrous Oxide Anesthesia for General Surgery , 1986, Anesthesiology.

[18]  D. Cox,et al.  A General Definition of Residuals , 1968 .

[19]  R. Maller,et al.  Survival Analysis with Long-Term Survivors , 1996 .

[20]  D J Sargent,et al.  A general framework for random effects survival analysis in the Cox proportional hazards setting. , 1998, Biometrics.

[21]  Sheldon M. Ross,et al.  Stochastic Processes , 2018, Gauge Integral Structures for Stochastic Calculus and Quantum Electrodynamics.

[22]  P. Grambsch,et al.  Martingale-based residuals for survival models , 1990 .

[23]  D R Stanski,et al.  Population pharmacodynamic model for ketorolac analgesia , 1996, Clinical pharmacology and therapeutics.